Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

60

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

60 results for “mortality by age”

Learn how ShareScore rates datasets ↗
dryad28/100

Data from: Aging in the natural world: comparative data reveal similar mortality patterns across primates

Open the record for dataset details and reuse information.

publicFeb 2011View details →
dryad28/100

Data from: Aging, mortality, and the fast growth trade-off of Schizosaccharomyces pombe

Open the record for dataset details and reuse information.

publicMay 2018View details →
geo24/100

Identification of a prognostic signature for old-age mortality by integrating genome-wide transcriptomic data with the conventional predictors: the Vitality 90+ Study

GEO Series GSE65218. Homo sapiens. 151 samples. Type: Expression profiling by array.

openGEO-OpenJan 2015View details →
geo24/100

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

GEO Series GSE190672. Mus musculus. 20 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2022View details →
geo24/100

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

GEO Series GSE190673. Mus musculus. 37 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2022View details →
geo24/100

Loss of the long non-coding RNA, Malat1, accelerates premature aging and mortality

GEO Series GSE130392. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2022View details →
ClinicalTrials.gov24/100

Morbidity and Mortality Rates Among Children Aged 0-59 Months

ClinicalTrials.gov study NCT06444958. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)

ClinicalTrials.gov study NCT02855372. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Biological Age Predicts 90-Day Mortality in Advanced Cancer

ClinicalTrials.gov study NCT07035470. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421

ClinicalTrials.gov study NCT02847065. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Impact of Age on Mortality in Critically Ill Adult Patients in Nepal- a Single Center Retrospective Study of 5 Years.

ClinicalTrials.gov study NCT06888206. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov24/100

Evaluation of the Clinical Frailty Scale (CFS) as a Risk Factor of Mortality in Adult Patients ≤65 Years of Age Admitted to Intensive Care for Septic Shock.

ClinicalTrials.gov study NCT05928767. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Age, Traumatic Brain Injury and Injury Severity as Independent Risk Factors for In-Hospital Mortality in Polytrauma Patients.

ClinicalTrials.gov study NCT04335838. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Study of the Short-term Mortality and Morbidity of Newborns Born at a Gestational Age <32 Weeks of Amenorrhea

ClinicalTrials.gov study NCT05150301. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Age-Dependent Impact of the SYNTAX-score on Mortality

ClinicalTrials.gov study NCT03479840. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Exercise and Mortality in Middle-Aged and Older Adults

ClinicalTrials.gov study NCT07224659. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo20/100

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

GEO Series GSE190674. Mus musculus. 57 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2022View details →
zenodo16/100

: Dataset related to the article "Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study"

<p>This record contains raw data related to the article &ldquo;Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study&rdquo;.</p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background:&nbsp;</strong>Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retrospective cohort study, we explored the association of circulating levels of soluble RAGE (sRAGE) isoforms, i.e., endogenous secretory esRAGE and cleaved cRAGE, AGEs and their respective ratios with 15-year all-cause mortality in type 2 diabetes.&nbsp;<strong>Methods:&nbsp;</strong>Baseline AGEs and sRAGE isoforms concentration were measured by ELISA in 362 patients with type 2 diabetes and in 125 age- and gender-matched healthy control subjects (CTR). Independent predictors of mortality were determined using Cox proportional-hazards models and used to build and validate a nomogram for all-cause mortality prediction in type 2 diabetes.&nbsp;<strong>Results:&nbsp;</strong>AGEs, total sRAGE, cRAGE and the AGEs/sRAGE and AGEs/esRAGE ratios were significantly increased in patients with type 2 diabetes compared to CTR (p &lt; 0.001). In CTR subjects, but not in type 2 diabetes patients, a significant negative correlation between cRAGE and age was confirmed (p = 0.003), whereas the AGEs/sRAGE (p = 0.032) and AGEs/cRAGE (p = 0.006) ratios were positively associated with age. At an average follow-up of 15 years (4,982 person-years), 130 deaths were observed. The increase in the AGEs/cRAGE ratio was accompanied by a higher risk of all-cause mortality in patients with type 2 diabetes (HR per each SD increment = 1.30, 95% CI 1.15-1.47; p &lt; 0.001). Moreover, sRAGE was associated with the development of major adverse cardiovascular events (MACE) in type 2 diabetes patients without previous MACE (OR for each SD increase: 1.48, 95% CI 1.11-1.89). A nomogram based on age, sex, HbA1c, systolic blood pressure, and the AGEs/cRAGE ratio was built to predict 5-, 10- and 15-year survival in type 2 diabetes. Patients were categorized into quartiles of the monogram scores and Kaplan-Meier survival curves confirmed the prognostic accuracy of the model (log-rank p = 6.5 &times; 10<sup>- 13</sup>).&nbsp;<strong>Conclusions:&nbsp;</strong>The ratio between AGEs and the cRAGE isoform is predictive of 15-year survival in patients with type 2 diabetes. Our data support the assessment of circulating AGEs and soluble RAGE isoforms in patients with type 2 diabetes as predictors of MACE and all-cause mortality.</p> Enable Ginger<em>Cannot connect to Ginger</em> Check your internet connection<br> or reload the browserDisable in this text fieldRephraseRephrase current sentence<span class="ginger-floatingG-bar-tool-mistakes-count">26</span>Log in to edit with Ginger&times;

restrictedJan 2023View details →
zenodo12/100

Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests

<p><strong>Introduction: </strong> The COVID-19 pandemic caused an increased mortality in nursing homes due to its quick spread and the age-related high lethality.</p> <p><strong>Results: </strong> We observed a two-month mortality of 40%, compared to 6.4% in the previous year. This increase was seen in both COVID-19 positive (43%) and negative (24%) residents, but 8 patients among those testing negative on the swab, tested positive on serological tests. Increased mortality was associated with male gender, older age, no previous vitamin D supplementation and worse &quot;activities of daily living (ADL)&quot; scores, such as Barthel index, Tinetti scale and S.OS.I.A.</p> <p><strong>Conclusion: </strong> Our data confirms a higher geriatric mortality due to COVID-19. Negative residents also had higher mortality, which we suspect is secondary to preanalytical error and a low sensitivity of the swab test in poorly compliant subjects. Male gender, older age and low scores on ADL scales (probably due to immobility) are risk factors for COVID-19 related mortality. Finally, mortality was inversely associated with vitamin D supplementation.</p> <p><strong>Design: </strong> In this observational study, we described the two-month mortality among the 157 residents (age 60-100) of a nursing home after Sars-CoV-2 spreading, reporting the factors associated with the outcome. We also compared the diagnostic tests for Sars-CoV-2.</p> <p>&nbsp; </p><p>https://pubmed.ncbi.nlm.nih.gov/33353888/</p> <p></p>

restrictedFeb 2021View details →
zenodo8/100

Dataset related to Study: "Age and comorbidity are crucial predictors of mortality in severe obstructive sleep apnoea syndrome".

<p><strong>ABSTRACT</strong>:&nbsp;The prognostic role of comorbidity in patients with severe obstructive sleep apnoea syndrome (OSAS) and their role for risk stratification remain incompletely studied and poorly defined. We studied 1,592 patients with severe OSAS diagnosed by polysomnography. The primary outcome was all-cause mortality. We used Poisson regression to estimate the standardized mortality ratio (SMR), compared with the general population. The association of comorbidities with all-cause mortality was assessed using multivariable Cox regression analysis. Then, we calculated pseudo-R&sup2; to measure the proportion of variation explained by the model. Finally, we applied recursive-partitioning analysis to cluster the patients into risk groups according to individual comorbidities. A total of 11,721 person-years of follow-up were examined during which 390 deaths (3.33 deaths/100 person-years) occurred. The median follow-up was 7 (4-10) years. The SMR was 1.47 (1.33-1.63). Age, sex, obesity, cardiovascular diseases (CVD), moderate-to-severe chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD) and malignancy were independently associated with mortality risk. The model had a C index of 0.811 and explained 63.2% of the variation in mortality risk. Recursive-partitioning analysis allowed distinguishing three clinical phenotypes differentially associated with mortality risk. The combination of CKD with CVDs or with moderate-to-severe COPD conferred the highest risk. The SMR was 2.56 (2.13-3.08) in the high-, 1.59 (1.37-1.85) in the intermediate-, and 0.91 (0.75-1.11) in the low-risk category. Severe OSAS is associated with increased risk for all-cause death. Age and comorbidity are crucial contributors to increased mortality in severe OSAS. Clustering patients according to comorbidities allows identifying clinically meaningful phenotypes.</p>

restrictedNov 2020View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.